Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1975]

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

POLO Trial: Olaparib as a maintenance treatment following first-line...

Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona...

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in...

Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas ( Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA )

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana

Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )

Novel therapies in the treatment of bladder cancer

Dr Petros Grivas and Dr Andrea Necchi

Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )

Clinical and translational results from the NEOSTAR study: Treating early-stage...

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...

Dr Edward B. Garon - UCLA, Los Angeles, USA

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona...

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

More from ecancer